These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 23732307)

  • 21. Effects of vaccination and the new neuraminidase inhibitor, laninamivir, on influenza infection.
    Mizuno T; Mizuno S; Kanda T
    PLoS One; 2014; 9(4):e92601. PubMed ID: 24699254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition.
    Vavricka CJ; Li Q; Wu Y; Qi J; Wang M; Liu Y; Gao F; Liu J; Feng E; He J; Wang J; Liu H; Jiang H; Gao GF
    PLoS Pathog; 2011 Oct; 7(10):e1002249. PubMed ID: 22028647
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The safety and efficacy of the long-acting neuraminidase inhibitor laninamivir octanoate hydrate for Inhalation Suspension Set in children under the age of 5 in a post-marketing surveillance.
    Nakano T; Yamaguchi H; Chiba T; Shiosakai K; Chikada S; Matsuoka Y
    J Infect Chemother; 2021 Oct; 27(10):1436-1446. PubMed ID: 34226112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts.
    Ikematsu H; Hayden FG; Kawaguchi K; Kinoshita M; de Jong MD; Lee N; Takashima S; Noshi T; Tsuchiya K; Uehara T
    N Engl J Med; 2020 Jul; 383(4):309-320. PubMed ID: 32640124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pregnancy outcomes of women exposed to laninamivir during pregnancy.
    Minakami H; Kubo T; Nakai A; Saito S; Unno N
    Pharmacoepidemiol Drug Saf; 2014 Oct; 23(10):1084-7. PubMed ID: 25074683
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate; comparison of the 2011/12 to 2015/16 Japanese influenza seasons.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
    J Infect Chemother; 2017 Sep; 23(9):627-633. PubMed ID: 28709902
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial.
    Monto AS; Robinson DP; Herlocher ML; Hinson JM; Elliott MJ; Crisp A
    JAMA; 1999 Jul; 282(1):31-5. PubMed ID: 10404908
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuraminidase inhibitors for preventing and treating influenza in adults and children.
    Jefferson T; Jones MA; Doshi P; Del Mar CB; Hama R; Thompson MJ; Spencer EA; Onakpoya I; Mahtani KR; Nunan D; Howick J; Heneghan CJ
    Cochrane Database Syst Rev; 2014 Apr; 2014(4):CD008965. PubMed ID: 24718923
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of a single inhalation of laninamivir octanoate in children with influenza.
    Katsumi Y; Otabe O; Matsui F; Kidowaki S; Mibayashi A; Tsuma Y; Ito H
    Pediatrics; 2012 Jun; 129(6):e1431-6. PubMed ID: 22614774
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study.
    Mäkelä MJ; Pauksens K; Rostila T; Fleming DM; Man CY; Keene ON; Webster A
    J Infect; 2000 Jan; 40(1):42-8. PubMed ID: 10762110
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single-dose inhaled laninamivir: registered in Japan and its potential role in control of influenza epidemics.
    Sunagawa S; Higa F; Cash HL; Tateyama M; Uno T; Fujita J
    Influenza Other Respir Viruses; 2013 Jan; 7(1):1-3. PubMed ID: 22405585
    [No Abstract]   [Full Text] [Related]  

  • 32. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial.
    Hedrick JA; Barzilai A; Behre U; Henderson FW; Hammond J; Reilly L; Keene O
    Pediatr Infect Dis J; 2000 May; 19(5):410-7. PubMed ID: 10819336
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Laninamivir octanoate and artificial surfactant combination therapy significantly increases survival of mice infected with lethal influenza H1N1 Virus.
    Fukushi M; Yamashita M; Miyoshi-Akiyama T; Kubo S; Yamamoto K; Kudo K
    PLoS One; 2012; 7(8):e42419. PubMed ID: 22879974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety evaluation of laninamivir octanoate hydrate through analysis of adverse events reported during early post-marketing phase vigilance.
    Nakano T; Okumura A; Tanabe T; Niwa S; Fukushima M; Yonemochi R; Eda H; Tsutsumi H
    Scand J Infect Dis; 2013 Jun; 45(6):469-77. PubMed ID: 23373850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.
    Hayden FG; Osterhaus AD; Treanor JJ; Fleming DM; Aoki FY; Nicholson KG; Bohnen AM; Hirst HM; Keene O; Wightman K
    N Engl J Med; 1997 Sep; 337(13):874-80. PubMed ID: 9302301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of a dry powder delivery system for laninamivir in a ferret model of influenza infection.
    Panozzo J; Oh DY; Margo K; Morton DA; Piedrafita D; Mosse J; Hurt AC
    Antiviral Res; 2015 Aug; 120():66-71. PubMed ID: 26022199
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical outcome of laninamivir octanoate hydrate for influenza in the 2013-2014 Japanese season.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
    J Infect Chemother; 2015 Nov; 21(11):802-7. PubMed ID: 26410550
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate for influenza treatment; comparison among the four Japanese influenza seasons from 2011-2012 to 2014-2015.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
    J Infect Chemother; 2016 Sep; 22(9):605-10. PubMed ID: 27493024
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Short-term treatment with zanamivir to prevent influenza: results of a placebo-controlled study.
    Kaiser L; Henry D; Flack NP; Keene O; Hayden FG
    Clin Infect Dis; 2000 Mar; 30(3):587-9. PubMed ID: 10722450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spotlight on zanamivir in influenza.
    Cheer SM; Wagstaff AJ
    Am J Respir Med; 2002; 1(2):147-52. PubMed ID: 14720068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.